相关临床试验
4
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1885
尚未招募
4
100.0%
暂无批准数据
- Researchers at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center received two NIH R01 grants totaling $7.5 million to study whether PFAS "forever chemicals" increase liver and endometrial cancer risk. - A $3.4 million grant will fund the first translational study of PFAS as a risk factor for hepatocellular carcinoma, combining Multiethnic Cohort Study data with human liver spheroid experiments. - A $4.1 million grant supports what researchers believe is the largest prospective study to date examining PFAS and endometrial cancer risk, using pre-diagnostic blood samples from 600 cases and 1,200 matched controls. - The studies aim to identify biological mechanisms linking PFAS exposure to cancer and inform policies to minimize exposure and reduce cancer burden.
- USC Center for Personalized Brain Health researchers have identified the enzyme cPLA2 as a key driver of neuroinflammation in APOE4 carriers who progress to Alzheimer's dementia. - The Norman and Mary Pattiz Foundation has donated $3 million to the Keck School of Medicine of USC to accelerate drug discovery, AI-driven small molecule screening, and early detection efforts. - The funding establishes a high-risk registry combining APOE4 genetic data with cardiovascular risk factors and supports neuropathologist Dr. Anne Hiniker in screening over 1,100 brain tissue samples for inflammatory markers. - The research aims to develop selective small-molecule therapies that inhibit cPLA2-driven inflammation while preserving normal cellular function.
- A new experimental compound SHP1705 specifically targets circadian clock proteins hijacked by glioblastoma stem cells, impairing their ability to survive and grow in preclinical studies. - SHP1705 has successfully completed a Phase 1 clinical trial with 54 healthy participants, demonstrating safety and tolerability with only minor side effects reported. - The compound functions as a CRY activator, enhancing CRY2 protein activity which is found at reduced levels in glioblastoma cells, and shows potential to enhance radiation therapy effectiveness.
- A comprehensive review by USC's Keck School of Medicine found that most FDA-approved COVID-19 treatments, particularly oral antivirals like Paxlovid, cause few serious side effects. - Monoclonal antibodies targeting the coronavirus spike protein showed no significant adverse events, while tocilizumab (Actemra) was associated with infection and low white blood cell counts in some studies. - Convalescent plasma transfusions were linked to higher risks of internal bleeding, infection, and blood clots, but all identified serious adverse events aligned with current product labeling.
- Mayo Clinic researchers have identified a connection between CAR T-cell aging and cancer relapse, providing new insights into treatment failure mechanisms. - The University of Texas MD Anderson Cancer Center conducted the largest study of its kind, identifying three distinct subgroups of large B-cell lymphoma patients with varying levels of benefit from CD19 CAR T-cell therapy. - The FDA has determined that Risk Evaluation and Mitigation Strategy (REMS) requirements are no longer necessary for CAR T-cell immunotherapies, reducing regulatory burden on healthcare systems. - USC researchers have developed an advanced analytical tool for studying CAR T-cells, including their evolution during manufacturing and effectiveness in cancer elimination.
